Future trials among HF patients without diabetes should clarify the predictors of incident diabetes among those with prediabetes and which patient phenotype is the most likely to benefit of SGLT2 inhibitors for diabetes prevention. This evidence concerns the gene SLC5A2 and hydrops fetalis.